Deloitte.

Health care reform and life sciences:

Threat, opportunity or both?

About the research



Respondents were from 3

What are executives saying about health care reforms around the world?

- Reducing costs
- Enhancing innovation
- Widening market access
- Changing sales models

Health care dramatically increasing

World — 2016 \$1558

2006 \$951





Almost half — number of executives who feel their company's response to health care reforms have tended to be reactive rather than part of broader, considered strategic change

What have executives being doing to address reform?

- approaches to national reforms
- Remodeling their innovation and sales activities
- Building/strengthening relationship with regulators

How important is health reform?

Very important or highest priority over last 3 years

Very important or highest priority over next 3 years

The challenges of reform

What are the biggest challenges that your

a result of healthcare reforms globally?

organisation has faced, or that you foresee as

- Developing country-specific

Adjusting our commercial models

Dealing with new/reformed government agencies

Developing comprehensive responses in different countries

Refocusing innovation

Providing value of our products

Responding to income reduction as a result of reforms

Which functions have seen the greatest increase in resources as part of your company's response to major government healthcare reforms in recent years?













Germany



Perspectives on health care reform from specific markets

Annual pharmaceutical spending per person 2012:



China

RaD activity, seeking formulary access, manufacturing, sale/ commercial activity — what over two-thirds of executives see an increase of in the China market over the next 3 years

- Dramatically rising public funding for health care
- Rising middle class

©2013. For information, contact Deloitte Touche Tohmatsu Limited. Source: Health care reform and life sciences: Threat, opportunity or both? (The Economist Intelligence Unit, Ltd.)

 Rapidly growing generics business New technologies increasing

- Value-based pricing
 - Generics benefiting from lower-cost environment Cited second most often,
 - after the US, as the country where health reforms present the biggest business model challenges